文献速递肾小球疾病遗传性与小管间质肾病

SAA1启动子突变导致遗传性淀粉样A淀粉样变性

A mutation in the SAA1 promoter causes hereditary amyloid A amyloidosis.
PubMed 文献 · Kidney Int · 2021-09-21

本文报道一个家系因SAA1启动子chr11:18287683 T>C突变(与淀粉样源性SAA1.1单倍型连锁)发生原发性淀粉样A淀粉样变性。该突变使SAA1启动子基础活性加倍,血清淀粉样A水平持续升高,呈常染色体显性遗传,12名遗传受累者均分离该突变而6名未受累者均无,LOD评分>5。患者出现蛋白尿、慢性肾脏病和SAA1.1亚型特异性系统性淀粉样沉积,早期使用托珠单抗有益。

要点

  • SAA1启动子T>C突变可致遗传性淀粉样A淀粉样变性,呈常染色体显性遗传。
  • 无系统性炎症的淀粉样A淀粉样变性患者,尤其有家族史者,应筛查SAA1启动子。
  • 早期使用托珠单抗(抗IL-6受体单抗)对本病有益。

核心结论

  • SAA1启动子chr11:18287683 T>C突变与淀粉样源性SAA1.1单倍型连锁,导致SAA1启动子基础活性加倍和血清淀粉样A持续升高,引发遗传性淀粉样A淀粉样变性。
  • 该家系中突变呈常染色体显性遗传,12名遗传受累者均分离突变而6名遗传未受累者均无,LOD评分>5。
  • 早期使用托珠单抗对病程有益。

研究设计与样本

  • 家系研究,纳入12名遗传受累者和6名遗传未受累亲属。
  • 通过基因分型分析chr11:18287683 T>C突变与疾病共分离,计算LOD评分。
  • 检测SAA1启动子活性及血清淀粉样A水平。

主要发现

  • 突变使SAA1启动子基础活性加倍,血清淀粉样A水平持续升高。
  • 12名遗传受累者均携带突变,6名遗传未受累者均不携带,LOD评分>5。
  • 患者出现蛋白尿、慢性肾脏病和SAA1.1亚型特异性系统性淀粉样沉积。
  • 早期使用托珠单抗有有益效果。

关键数值与推荐

  • SAA1启动子突变位于chr11:18287683 T>C(human genome version19),与淀粉样源性SAA1.1单倍型连锁。
  • 特发性形式占所有诊断淀粉样A淀粉样变性病例的15-20%。
  • LOD评分>5。

临床怎么用

  • 对无系统性炎症的淀粉样A淀粉样变性患者,尤其有阳性家族史者,应进行SAA1启动子基因筛查。
  • 早期识别SAA1启动子突变携带者并尽早使用托珠单抗可能有益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Amyloid A amyloidosis is a serious clinical condition resulting from the systemic deposition of amyloid A originating from serum amyloid A proteins with the kidneys being the most commonly and earliest affected organ. Previously described amyloid A amyloidosis is linked to increased production and deposition of serum amyloid A proteins secondary to inflammatory conditions arising from infectious, metabolic, or genetic causes. Here we describe a family with primary amyloid A amyloidosis due to a chr11:18287683 T>C (human genome version19) mutation in the SAA1 promoter linked to the amyloidogenic SAA1.1 haplotype. This condition leads to a doubling of the basal SAA1 promoter activity and sustained elevation of serum amyloid A levels that segregated in an autosomal dominant pattern in 12 genetically affected and in none of six genetically unaffected relatives, yielding a statistically significant logarithm of odds (LOD) score over 5. Affected individuals developed proteinuria, chronic kidney disease and systemic deposition of amyloid composed specifically of the SAA1.1 isoform. Tocilizumab (a monoclonal antibody against the interleukin-6 receptor) had a beneficial effect when prescribed early in the disease course. Idiopathic forms represent a significant and increasing proportion (15-20%) of all diagnosed cases of amyloid A amyloidosis. Thus, genetic screening of the SAA1 promoter should be pursued in individuals with amyloid A amyloidosis and no systemic inflammation, especially if there is a positive family history.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Sikora J, Kmochová T, Mušálková D, et al. A mutation in the SAA1 promoter causes hereditary amyloid A amyloidosis. Kidney Int. 2021. PMID: 34560138. doi:10.1016/j.kint.2021.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。